

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 June 2022 (02.06.2022)



(10) International Publication Number
WO 2022/112942 A3

(51) International Patent Classification:
C07K 16/28 (2006.01) A61P 35/00 (2006.01)
A61K 47/68 (2017.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/IB2021/060871

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:
23 November 2021 (23.11.2021)

(25) Filing Language: English

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(26) Publication Language: English

(30) Priority Data:
63/117,817 24 November 2020 (24.11.2020) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(88) Date of publication of the international search report:

14 July 2022 (14.07.2022)

(72) Inventors: **D'ALESSIO, Joseph Anthony**; c/o Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts
Avenue, Cambridge, Massachusetts 02139 (US). **KLIN-
TER, Claudia Judith**; c/o Novartis Pharma AG, Post-
fach, 4002 Basel (CH). **MUNDT, Cornelia Anne**; c/o
Novartis Pharma AG, Postfach, 4002 Basel (CH). **NEW-
COMBE, Richard Vaughan**; c/o Novartis Institutes for
BioMedical Research, Inc., 250 Massachusetts Avenue,
Cambridge, Massachusetts 02139 (US). **SCHWEIGHOF-
FER, Tamás**; Dinkelbergstrasse 40, 4125 Riehen (CH).
WINKELBACH, Katharina; c/o Novartis Pharma AG,
Postfach, 4002 Basel (CH).

(74) Agent: **NOVARTIS AG**; Lichtstrasse 35, 4056 Basel
(CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF

(57) Abstract: Disclosed herein are antibodies, antigen binding fragments thereof, and antibody drug conjugates thereof that bind human CD48. Also disclosed are pharmaceutical compositions comprising the antibodies, antigen binding fragments thereof, and antibody drug conjugates thereof; and methods of making and using such pharmaceutical compositions for treating cancer in a patient in need of treatment.

WO 2022/112942 A3